ANAB (STOCKS)
AnaptysBio, Inc. Common Stock
$68.700000
-1.400000 (-2.00%)
Prev close: $70.100000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Daniel R. Faga
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,974.29M
- Employees
- 136
- P/E (TTM)
- -134.68
- P/B (TTM)
- 52.79
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
10
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$1.58 | $0.96 | +0.6227 | +65.05% |
|
Sep 2025 (Q3)
|
$0.52 | $-1.47 | +1.9881 | +135.42% |
|
Jun 2025 (Q2)
|
$-1.34 | $-1.57 | +0.2325 | +14.79% |
|
Mar 2025 (Q1)
|
$-1.28 | $-1.28 | -0.0015 | -0.12% |
Financial Statements
| Revenues | $234.60M |
| Benefits Costs and Expenses | $247.67M |
| Costs And Expenses | $247.67M |
| Nonoperating Income/Loss | -$60.96M |
| Operating Expenses | $186.71M |
| Operating Income/Loss | $47.90M |
| Income/Loss From Continuing Operations After Tax | -$13.23M |
| Income/Loss From Continuing Operations Before Tax | -$13.07M |
| Income Tax Expense/Benefit | $164.00K |
| Net Income/Loss | -$13.23M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$13.23M |
| Net Income/Loss Available To Common Stockholders, Basic | -$13.23M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.46 |
| Diluted Earnings Per Share | -$0.46 |
| Basic Average Shares | 28,758,000 |
| Diluted Average Shares | 28,758,000 |
| Assets | $364.40M |
| Current Assets | $350.25M |
| Accounts Receivable | $33.85M |
| Other Current Assets | $316.40M |
| Noncurrent Assets | $14.15M |
| Fixed Assets | $1.37M |
| Other Non-current Assets | $12.78M |
| Liabilities | $327.19M |
| Current Liabilities | $38.63M |
| Accounts Payable | $3.87M |
| Wages | $11.09M |
| Other Current Liabilities | $23.66M |
| Noncurrent Liabilities | $288.56M |
| Equity | $37.21M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $37.21M |
| Liabilities And Equity | $364.40M |
| Net Cash Flow From Operating Activities | $19.70M |
| Net Cash Flow From Operating Activities, Continuing | $19.70M |
| Net Cash Flow From Investing Activities | $228.03M |
| Net Cash Flow From Investing Activities, Continuing | $228.03M |
| Net Cash Flow From Financing Activities | -$132.61M |
| Net Cash Flow From Financing Activities, Continuing | -$132.61M |
| Net Cash Flow | $115.12M |
| Net Cash Flow, Continuing | $115.12M |
| Comprehensive Income/Loss | -$13.56M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$13.56M |
| Other Comprehensive Income/Loss | -$13.56M |
| Other Comprehensive Income/Loss Attributable To Parent | -$329.00K |